Modulation of cell death in the tumor microenvironment

Seminars in Radiation Oncology

Volumn 13, Issue 1, 2003, Pages 31-41

  Wouters, Bradly G ^a   Koritzinsky, Marianne ^a   Chiu, Roland K ^a   Theys, Jan ^a   Buijsen, Jeroen ^a   Lambin, Philippe ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ADENOSINE TRIPHOSPHATE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BIOREDUCTIVE DRUG; CARBOGEN; CISPLATIN; GLUCOSE TRANSPORTER; NICOTINAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PRODRUG; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; TIRAPAZAMINE; UNCLASSIFIED DRUG; WORTMANNIN;

ANIMAL CELL; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DRUG ACTIVATION; DRUG EFFECT; GENE THERAPY; HUMAN; HUMAN CELL; HYPOXIA; HYPOXIC CELL; METASTASIS; MICROENVIRONMENT; MULTIMODALITY CANCER THERAPY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OXYGENATION; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REDUCTION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR CELL CULTURE; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 0037267568     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1053/srao.2003.50004     Document Type: Review

References (120)

1. Gray LH, Conger AD, Ebert M, et al: Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26:638-648, 1953
2. Young SD, Marshall RS, Hill RP: Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci U S A 85:9533-9537, 1988
3. De Jaeger K, Kavanagh MC, Hill RP: Relationship of hypoxia to metastatic ability in rodent tumours. Br J Cancer 84:1280-1285, 2001
4. Graeber TG, Osmanian C, Jacks T, et al: Hypoxiamediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:88-91, 1996
5. Kim CY, Tsai MH, Osmanian C, et al: Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. Cancer Res 57:4200-4204, 1997
6. Rofstad EK, Danielsen T: Hypoxia-induced metastasis of human melanoma cells: Involvement of vascular endothelial growth factor-mediated angiogenesis. Br J Cancer 80:1697-1707, 1999
7. Royds JA, Dower SK, Qwarnstrom EE, et al: Response of tumour cells to hypoxia: Role of p53 and NFkB. Mol Pathol 51:55-61, 1998
8. Semenza GL: Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 35:71-103, 2000
9. Hockel M, Schlenger K, Aral B, et al: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56:4509-15, 1996
10. Brizel DM, Sibley GS, Prosnitz LR, et al: Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38:285-289, 1997
11. Nordsmark M, Alsner J, Keller J, et al: Hypoxia in human soft tissue sarcomas: Adverse impact on survival and no association with p53 mutations. Br J Cancer 84:1070-1075, 2001
12. Semenza GL: Regulation of hypoxia-induced angiogenesis: A chaperone escorts VEGF to the dance. J Clin Invest 108:39-40, 2001
13. Lartigau E, Le Ridant AM, Lambin P, et al: Oxygenation of head and neck tumors. Cancer 71:2319-2325, 1993
14. Martin L, Lartigau E, Weeger P, et al: Changes in the oxygenation of head and neck tumors during carbogen breathing. Radiother Oncol 27:123-130, 1993
15. Nordsmark M, Overgaard M, Overgaard J: Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41:31-39, 1996
16. Kimura H, Braun RD, Ong ET, et al: Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 56:5522-5528, 1996
17. Brown EB, Campbell RB, Tsuzuki Y, et al: In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat Med 7:864-868, 2001
18. Rofstad EK: Microenvironment-induced cancer metastasis. Int J Radiat Biol 76:589-605, 2000
19. Yuan J, Glazer PM: Mutagenesis induced by the tumor microenvironment. Mutat Res 400:439-446, 1998
20. Hockel M, Vaupel P: Biological consequences of tumor hypoxia. Semin Oncol 28:36-41, 2001
21. Ferrara N, Chen H, Davis-Smyth T, et al: Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 4:336-340, 1998
22. Hobson B, Denekamp J: Endothelial proliferation in turnouts and normal tissues: continuous labelling studies. Br J Cancer 49:405-413, 1984
23. Semenza GL: Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15:551-578, 1999
24. Koong AC, Denko NC, Hudson KM, et al: Candidate genes for the hypoxic tumor phenotype. Cancer Res 60:883-887, 2000
25. Sowter HM, Ratcliffe PJ, Watson P, et al: HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res 61:6669-6673, 2001
26. Bruick RK: Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci U S A 97:9082-9087, 2000
27. Green DR, Evan GI: A matter of life and death. Cancer Cell 1:19-30, 2002
28. Magnusson KP, Satalino R, Qian W, et al: Is conversion of solid into more anoxic ascites tumors associated with p53 inactivation? Oncogene 17:2333-2337, 1998
29. Kinoshita M, Johnson DL, Shatney CH, et al: Cancer cells surviving hypoxia obtain hypoxia resistance and maintain anti-apoptotic potential under reoxygenation. Int J Cancer 91:322-326, 2001
30. Liang BC: Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. J Neurooncol 29:149-155, 1996
31. Walenta S, Snyder S, Haroon ZA, et al: Tissue gradients of energy metabolites mirror oxygen tension gradients in a rat mammary carcinoma model. Int J Radiat Oncol Biol Phys 51:840-848, 2001
32. Sivitz WI, Lund DD, Yorek B, et al: Pretranslational regulation of two cardiac glucose transporters in rats exposed to hypobaric hypoxia. Am J Physiol 263:E562-569, 1992
33. Firth JD, Ebert BL, Pugh CW, et al: Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: Similarities with the erythropoietin 3′ enhancer. Proc Natl Acad Sci U S A 91:6496-500, 1994
34. Semenza GL, Roth PH, Fang HM, et al: Transcriptional regulation of genes encoding glycolytic enzymes by hvpoxia-inducible factor 1. J Biol Chem 269:23757-23763, 1994
35. Maxwell PH, Wiesener MS, Chang GW, et al: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275, 1999
36. Jaakkola P, Mole DR, Tian YM, et al: Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regutated prolyl hydroxylation. Science 292: 468-472, 2001
37. Ivan M, Kondo K, Yang H, et al: HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 292:464-468, 2001
38. Williams KJ, Telfer BA, Airley RE, et al: A protective role for HIF-1 in response to redox manipulation and glucose deprivation: Implications for tumorigenesis. Oncogene 21:282-290, 2002
39. Seagroves TN, Ryan HE, Lu H, et al: Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol Cell Biol 21:3436-3444, 2001
40. Williams KJ, Telfer BA, Airley RE, et al: A protective role for HIF-1 in response to redox manipulation and glucose deprivation: Implications for tumorigenesis. Oncogene 21:282-290, 2002
41. Dang CV, Semenza GL: Oncogenic alterations of metabolism. Trends Biochem Sci 24:68-72, 1999
42. Sutherland R, Freyer J, Mueller-Klieser W, et al: Cellular growth and metabolic adaptations to nutrient stress environments in tumor microregions. Int J Radiat Oncol Biol Phys 12:611-615, 1986
43. Koch CJ: Oxygen effects in radiobiology. Adv Exp Med Biol 157:123-144, 1982
44. Sutherland R, Freyer J, Mueller-Klieser W, et al: Cellular growth and metabolic adaptations to nutrient stress environments in tumor microregions. Int J Radiat Oncol Biol Phys 12:611-615, 1986
45. Hochachka PW, Buck LT, Doll QJ, et al: Unifying theory of hypoxia tolerance: Molecular/metabolic defense and rescue mechanisms for surviving oxygen lack. Proc Natl Acad Sci U S A 93:9493-9498, 1996
46. Pettersen EO, Juul NO, Ronning OW: Regulation of protein metabolism of human cells during and after acute hypoxia. Cancer Res 46:4346-4351, 1986
47. Lefebvre VH, Van Steenbrugge M, Beckers V, et al: Adenine nucleotides and inhibition of protein synthesis in isolated hepatocytes incubated under different pO2 levels. Arch Biochem Biophys 304:322-331, 1993
48. Hershey JW, Merrick WC: Pathway and mechanism of initiation of protein synthesis, in Sonenberg N, Hershey JW, Mathews MB (eds): Translational control of gene expression. Cold Spring Harbor, Cols Spring Harbor Laboratory Press, 2000, pp 33-88
49. Koumenis C, Naczki C, Koritzinsky M, et al: Regulation of protein synthesis by hypoxia via activation of the protein kinase PERK and phosphorylation of e1F2atpha. Mol Cell Biol 22:7405-7416, 2002
50. Koritzinsky M, Koumenis C, Sonenberg N, et al: Regulation of protein translation during hypoxic conditions. Paper presented at the 93rd Annual Meeting of the American Association for Cancer Research, San Francsico, CA, April 6-10, 2002
51. Wouters BG, Weppler SA, Koritzinsky M, et al: Hypoxia as a target for combined modality treatments. Eur J Cancer 38:240-257, 2002
52. Overgaard J, Horsman MR: Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 6:10-21, 1996
53. Saunders M, Dische S: Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide. Br J Cancer 27:S271-S278, 1996 (Suppl)
54. Overgaard J: Sensitization of hypoxic tumour cells - Clinical experience. Int J Radiat Biol 56:801-811, 1989
55. Pedersen D, Sogaard H, Overgaard J, et al: Prognostic value of pretreatment factors in patients with locally advanced carcinoma of the uterine cervix treated by radiotherapy alone. Acta Oncol 34:787-795, 1995
56. Girinski T, Pejovic-Lenfant MH, Bourhis J, et al: Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: Results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys 16:37-42, 1989
57. Fein DA, Lee WR, Hanlon AL, et al: Pretreatment hemoglobin level influences local control and survival of TI-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 13:2077-2083, 1995
58. Lee WR, Berkey B, Marcial V, et al: Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: A secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 42:1069-1075, 1998
59. van Acht MJ, Hermans J, Boks DE, et al: The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma. Radiother Oncol 23:229-235, 1992
60. Warde P, O'Sullivan B, Bristow RG, et al: T1/T2 glottic cancer managed by external beam radiotherapy: The influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys 41:347-353, 1998
61. Dubray B, Mosseri V, Brunin F, et al: Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology 201:553-558, 1996
62. Dische S, Warburton MF, Saunders MI: Radiation myelitis and survival in the radiotherapy of lung cancer. Int J Radiat Oncol Biol Phys 15:75-81, 1988
63. Macchiarini P, Silvano G, Janni A, et al: Results of treatment and lessons learned from pathologically staged T4 non-small cell lung cancer. J Surg Oncol 47:209-214, 1991
64. Sasai K, Ono K, Hiraoka M, et al: The effect of arterial oxygen content on the results of radiation therapy for epidermoid bronchogenic carcinoma. Int J Radiat Oncol Biol Phys 16:1477-1481, 1989
65. Cole CJ, Pollack A, Zagars GK, et al: Local control of muscle-invasive bladder cancer: Preoperative radiotherapy and cystectomy versus cystectomy alone. Int J Radiat Oncol Biol Phys 32:331-340, 1995
66. Hannisdal E, Fossa SD, Host H: Blood tests and prognosis in bladder carcinomas treated with definitive radiotherapy. Radiother Oncol 27:117-122, 1993
67. Wijkstrom H, Nilsson B, Tribukait B: DNA analysis in predicting survival of irradiated patients with transitional cell carcinoma of bladder. Br J Urol 69:49-55, 1992
68. Greven KM, Solin LJ, Hanks GE: Prognostic factors in patients with bladder carcinoma treated with definitive irradiation. Cancer 65:908-912, 1990
69. Dunphy EP, Petersen IA, Cox RS, et al: The influence of initial hemoglobin and blood pressure levels on results of radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 16:1173-1178, 1989
70. Rojas A, Joiner MC, Denekamp J: Extrapolations from laboratory and preclinical studies for the use ofcarbogen and nicotinamide in radiotherapy. Radiother Oncol 24: 123-124, 1992
71. Chaplin DJ, Horsman MR, Trotter MJ: Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumor. J Natl Cancer Inst 82:672-676, 1990
72. Rojas A: Radiosensitization with normobaric oxygen and carbogen. Radiother Oncol 1:65-70, 1991 (Suppl)
73. Horsman MR, Nordsmark M, Khalil AA, et al: Reducing acute and chronic hypoxia in tumours by combining nicotinamide with carbogen breathing. Acta Oncol 33: 371-376, 1994
74. Laurence VM, Ward R, Dennis IF, et al: Carbogen breathing with nicotinamide improves the oxygen status of tumours in patients. Br J Cancer 72:198-205, 1995
75. Kaanders JH, Pop LA, Marres HA, et al: Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. Radiother Oncol 48:115-122, 1998
76. Bussink J, Kaanders JH, Van der Kogel AJ: Clinical outcome and tumour microenvironmental effects of accelerated radiotherapy with carbogen and nicotinamide. Acta Oncol 38:875-882, 1999
77. Kaanders JH, Pop LA, Marres HA, et al: ARCON: Experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 52:769-778, 2002
78. Hoskin PJ, Saunders MI, Dische S: Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: Hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide. Cancer 86:1322-1328, 1999
79. Bernier J, Denekamp J, Rojas A, et al: ARCON: Accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the european organization for research and treatment of cancer (EORTC). Radiother Oncol 55:111-1199, 2000
80. Brown JM, Koong A: Therapeutic advantage of hypoxic cells in tumors: A theoretical study. J Natl Cancer Inst 83:178-185, 1991
81. Wouters BG, Wang LH, Brown JM: Tirapazamine: a new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer. Ann Oncol 10:S29-33, 1999
82. Brown JM: SR 4233 (tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67:1163-1170, 1993
83. Lambin P, Theys J, Landuyt W, et al: Colonisation of Clostridium in the body is restricted to hypoxic and necrotic areas of tumors. Anaerobe 4:183-188, 1998
84. Pawelek JM, Low KB, Bermudes D: Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 57:4537-4544, 1997
85. Lemmon MJ, van Zijl P, Fox ME, et al: Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther 4:791-796, 1997
86. Theys J, Landuyt W, Nuyts S, et al: Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Ther 8:294-297, 2001
87. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186, 1971
88. McNamara DA, Harmey JH, Walsh TN, et al: Significance of angiogenesis in cancer therapy. Br J Surg 85: 1044-1055, 1998
89. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843-845, 1992
90. Stein I, Neeman M, Shweiki D, Itin A, et al: Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemiainduced genes. Mol Cell Biol 15:5363-5368, 1995
91. Forsythe JA, Jiang BH, Iyer NV, et al: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604-4613, 1996
92. Plate KH, Breier G, Millauer B, Ullrich A, Risau W: Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 53:5822-5827, 1993
93. Fong TA, Shawver LK, Sun L, et al: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-l/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59:99-106, 1999
94. Laird AD, Vajkoczy P, Shawver LK, et al: SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60:4152-4160, 2000
95. Wood JM, Bold G, Buchdunger E, et al: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178-2189, 2000
96. Usman N, Blatt LM: Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. J Clin Invest 106:1197-1202, 2000
97. Rubenstein JL, Kim J, Ozawa T, et al: Anti-VEGF anti-body treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306-314, 2000
98. O'Reilly MS: Angiostatin: An endogenous inhibitor of angiogenesis and of tumor growth. Exs 79:273-294, 1997
99. O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285, 1997
100. Figg WD, Dahut W, Duray P, et al: A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7:1888-1893, 2001
101. Zetter BR: Angiogenesis and tumor metastasis. Annu Rev Med 49:407-424, 1998
102. Min HY, Doyle LV, Vitt CR, et al: Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 56:2428-2433, 1996
103. Li H, Lu H, Griscelli F, et al: Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther 5:1103-1113, 1998
104. Eliceiri BP, Cheresh DA: The role of alphav integrins during angiogenesis: Insights into potential mechanisms of action and clinical development. J Clin Invest 103: 1227-1230, 1999
105. Reynolds LE, Wyder L, Lively JC, et al: Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 8:27-34, 2002
106. Carmeliet P: Integrin indecision. Nat Med 8:14-6, 2002
107. Yu JL, Rak JW, Coomber BL, et al: Effect of p53 status on tumor response to antiangiogenic therapy. Science 295:1526-1528, 2002
108. Kerbel RS, Yu J, Tran J, et al: Possible mechanisms of acquired resistance to anti-angiogenic drugs: Implications for the use of combination therapy approaches. Cancer Metastasis Rev 20:79-86, 2001
109. Yu JL, Rak JW, Carmeliet P, et al: Heterogeneous vascular dependence of tumor cell populations. Am J Pathol 158:1325-1334, 2001
110. Zundel W, Schindler C, Haas-Kogan D, et al: Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14:391-396, 2000
111. Zhong H, Chiles K, Feldser D, et al: Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/ PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541-1545, 2000
112. Chang EH, Miller PS, Cushman C, et al: Antisense inhibition of ras p21 expression that is sensitive to a point mutation. Biochemistry 30:8283-8286, 1991
113. Feng M, Cabrera G, Deshane J, et al: Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res 55: 2024-2028, 1995
114. Richardson JH, Marasco WA: Intracellular antibodies: Development and therapeutic potential. Trends Biotechnol 13:306-310, 1995
115. Izumi Y, Xu L, di Tomaso E, et al: Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 416:279-280, 2002
116. Herbst RS, Langer QJ: Epidermal growth factor receptors as a target for cancer treatment: The emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 29:27-36, 2002
117. Eastham JA, Hall Sj, Sehgal I, et al: In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55:5151-5155, 1995
118. Roth JA, Nguyen D, Lawrence DD, et al: Retrovirusmediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2:985-991, 1996
119. Vigneri P, Wang JY: Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 7:228-234, 2001
120. Chen YN, Sharma SK, Ramsey TM, et al: Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci U S A 96:4325-4329, 1999